Amerise Biosciences Ltd
Amerise Biosciences Ltd (AMERISE) last reported results for the quarter ended Jun 2026, with sales of ₹0 crore and net profit of ₹-0.08 crore. The stock last traded at ₹0.79, a market capitalisation of ₹5.22 crore. Over the past 52 weeks the stock has ranged between ₹0.5 and ₹1.03. Figures are as of 6 Oct 2026 and are not real time.
Amerise Biosciences Ltd share price and key metrics
- Current price
- ₹0.79
- Market cap
- ₹5.22 cr
- Book value
- ₹0.82
- ROE
- 0.37%
- ROCE
- 0.37%
- Dividend yield
- 0.00%
- 52w high / low
- 1.03/0.50
Metrics as of 6 Oct 2026. Not real time.
Track Amerise Biosciences Ltd
Cruxal reads every Amerise Biosciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Amerise Biosciences Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -24%
- 10 Years
- 10%
- 5 Years
- 16%
- 3 Years
- 29%
- TTM
- -200%
- 10 Years
- -6%
- 5 Years
- -14%
- 3 Years
- 10%
- 1 Year
- 23%
- 10 Years
- -2%
- 5 Years
- 1%
- 3 Years
- -1%
- Last Year
- 0%
Amerise Biosciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹0 cr, down 100.0% from ₹0.06 cr a year earlier. Net profit was ₹-0.08 cr, down 700.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0.19 | 0.06 | 0.07 | 0.04 | 0.08 | 0 |
| Expenses | 0.03 | 0.02 | 0.08 | 0.07 | 0.11 | 0.03 | 0.02 | 0.08 |
| Operating profit | -0.03 | -0.02 | 0.11 | -0.01 | -0.04 | 0.01 | 0.06 | -0.08 |
| OPM % | — | — | 57.89% | -16.67% | -57.14% | 25.00% | 75.00% | — |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -0.03 | -0.02 | 0.11 | -0.01 | -0.04 | 0.01 | 0.06 | -0.08 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net profit | -0.03 | -0.02 | 0.11 | -0.01 | -0.04 | 0.01 | 0.06 | -0.08 |
| EPS (₹) | -0.00 | -0.00 | 0.02 | -0.00 | -0.01 | 0.00 | 0.01 | -0.01 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Amerise Biosciences Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 1.18 | 0 | 0 | 9.58 | 0.01 | 0.04 | 0 | 0 | 0.19 |
| Operating profit | -0.94 | -0.02 | 0 | -0.15 | -0.17 | 0.55 | -0.12 | -0.15 | -0.18 | -0.24 | -0.05 |
| OPM % | — | — | 0.00% | — | — | 5.74% | -1,200.00% | -375.00% | 5.26% | 7.69% | -26.32% |
| Net profit | -0.94 | -0.02 | 0 | -0.15 | -0.34 | 0.55 | -0.12 | -0.15 | 0.01 | 0.02 | -0.05 |
| EPS (₹) | -0.14 | -0.00 | 0.00 | -0.02 | -0.05 | 0.08 | -0.02 | -0.02 | 0.00 | 0.00 | -0.01 |
TTM is the trailing twelve months to the most recent quarter.
Amerise Biosciences Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 |
| Reserves | -1.01 | -1.03 | -1.03 | -1.18 | -1.52 | -0.97 | -1.09 | -1.23 | -1.23 | -1.21 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.09 | 0.00 | 0.00 | 0.00 |
| Other liabilities | 0.04 | 0.01 | 0.02 | 0.60 | 0.54 | 6.27 | 0.04 | 0.01 | 3.08 | 2.03 |
| Total liabilities | 5.64 | 5.59 | 5.60 | 6.03 | 5.63 | 11.99 | 5.65 | 5.39 | 8.46 | 7.43 |
| Fixed assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 2.34 | 2.31 | 0.54 | 5.37 | 3.04 | 4.69 | 4.57 | 2.27 | 2.38 | 3.77 |
| Other assets | 3.30 | 3.28 | 5.06 | 0.66 | 2.59 | 7.30 | 1.08 | 3.12 | 6.08 | 3.66 |
| Total assets | 5.64 | 5.59 | 5.60 | 6.03 | 5.63 | 11.99 | 5.65 | 5.39 | 8.46 | 7.43 |
As reported by the company. Total assets equal total liabilities by construction.
Amerise Biosciences Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -3.56 | -0.04 | -1.78 | 4.89 | -0.39 | 0.06 | -0.13 | -0.17 | 3.07 | -1.06 |
| Cash from investing | 3.55 | 0.03 | 1.77 | -4.89 | 0.39 | -0.15 | 0.13 | 0.27 | -3.07 | 1.63 |
| Cash from financing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.01 | -0.09 | 0.00 | 0.00 |
| Net cash flow | -0.01 | -0.01 | -0.01 | 0.01 | -0.01 | -0.01 | 0.00 | 0.01 | 0.00 | 0.57 |
| Free cash flow | -3.56 | -0.04 | -1.78 | 4.89 | -0.39 | 0.06 | -0.13 | -0.17 | 3.07 | -1.06 |
| CFO / operating profit | 379% | 200% | — | -3,260% | 229% | 11% | 108% | 113% | -1,706% | 442% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Amerise Biosciences Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | -15.49% | -0.36% | 0.00% | -2.72% | -6.46% | 10.18% | -2.12% | -2.73% | 0.19% | 0.37% |
| Debtor days | — | — | 1,382.67 | — | — | 236.98 | 0.00 | 0.00 | — | — |
| Inventory days | — | — | 0.00 | — | — | 0.00 | — | — | — | — |
| Cash conversion cycle | — | — | 1,382.67 | — | — | 236.98 | 0.00 | 0.00 | — | — |
| Working capital days | — | — | 1,376.48 | — | — | -1.91 | -1,460.00 | -182.50 | — | — |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Amerise Biosciences Ltd shareholding pattern
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Public | 100.00% | 100.00% | 100.00% | 99.99% | 100.00% | 99.99% | 100.00% | 100.00% |
| No. of shareholders | 27,077 | 35,142 | 36,595 | 36,217 | 35,676 | 35,180 | 34,519 | 33,848 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Amerise Biosciences Ltd corporate filings
- Company Website Update by Amerise Biosciences Ltd (531681)Company Updatelow impact
Cruxal's analysis: Amerise Biosciences Ltd has made an update to its website as of October 10, 2026. The…
Read the full analysis - PFACompany Updatelow impact
- Amerise Biosciences Limited Announces Voting Results of 41st Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: Amerise Biosciences Limited has disclosed the voting results for its 41st Annual General…
Read the full analysis - Amerise Biosciences Limited concludes 41st Annual General Meeting and appoints new Wholetime Director and CFOAGM/EGMlow impact
Cruxal's analysis: Amerise Biosciences Limited has successfully concluded its 41st Annual General Meeting…
Read the full analysis - PFAInsider Trading / SASTlow impact
- Amerise Biosciences Ltd submits Annual Report for FY 2025-26 and schedules 41st AGM for September 24, 2026Otherslow impact
Cruxal's analysis: Amerise Biosciences has filed its Annual Report for the financial year 2025-26 in…
Read the full analysis - Amerise Biosciences Ltd announces book closure for upcoming corporate eventCorp. Actionlow impact
Cruxal's analysis: Amerise Biosciences Ltd has issued an intimation regarding book closure in compliance…
Read the full analysis - Amerise Biosciences Limited announces 41st Annual General Meeting and formalizes appointment of Whole-Time Director and CFOAGM/EGMlow impact
Cruxal's analysis: Amerise Biosciences Limited has issued a notice for its 41st Annual General Meeting…
Read the full analysis - Snehjeev Ventures Increases Stake in Amerise Biosciences Ltd to 11.04% via Open Market AcquisitionInsider Trading / SASTmedium impact
Cruxal's analysis: Snehjeev Ventures Pvt. Ltd., along with Persons Acting in Concert (PAC), has acquired…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.